While care was taken to exclude other neurological conditions other than probable Alzheimer’s Disease, participants in the current cohort have not, to date, been assessed with other methods making up the AT(N) framework such as amyloid or tau-PET, which would inform a biological diagnosis of Alzheimer’s disease. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.